We attended the NICE appraisal committee meeting for bosutinib yesterday in Manchester. David and Russell represented CML patients and did very well to get over the salient points about why CML patients need a choice of TKIs- including bosutinib (Bosulif). 2 CML clinicians were excellent and gave very clear and robust reasons for why bosutinib is a good addition to the arsenal of TKI therapies. Of course as we all know it does depend on how the economic assessment pans out (i.e price)- but we are ever hopeful that this TKi will be approved by NICE, if not now then at some point in the near future. I would like to thank both David and Russell for writing the submissions and for doing so well during the committee meeting- not an easy ride!
I will update here as soon as NICE have published their decision (approx. 3-4 weeks).
Sandy